What is a primary action of Pramlintide (Symlin) in Type 1 diabetes management?

Pramlintide (Symlin) is primarily known for its action of delaying gastric emptying. This mechanism plays a significant role in the management of Type 1 diabetes by slowing down the rate at which food leaves the stomach and enters the intestines. As a result, this leads to a more gradual and sustained release of glucose into the bloodstream, helping to prevent spikes in blood sugar levels following meals. In addition to delaying gastric emptying, Pramlintide also suppresses glucagon secretion, which further aids in maintaining more stable blood glucose levels after meals.

The other options do not accurately describe the primary action of Pramlintide. While it does not stimulate insulin secretion or increase appetite, these functions are more associated with other hormonal actions or medications. Moreover, Pramlintide does not reduce insulin sensitivity; rather, it works synergistically with insulin to improve glycemic control in individuals with Type 1 diabetes.